These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 21835788)

  • 1. Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
    Wang J; Zhang G; Bambara RA; Li D; Liang H; Wu H; Smith HM; Lowe NR; Demeter LM; Dykes C
    J Virol; 2011 Oct; 85(20):10861-73. PubMed ID: 21835788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.
    Wang J; Liang H; Bacheler L; Wu H; Deriziotis K; Demeter LM; Dykes C
    Virology; 2010 Jul; 402(2):228-37. PubMed ID: 20399480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
    Xu HT; Colby-Germinario SP; Huang W; Oliveira M; Han Y; Quan Y; Petropoulos CJ; Wainberg MA
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5649-57. PubMed ID: 24002090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
    Reuman EC; Rhee SY; Holmes SP; Shafer RW
    J Antimicrob Chemother; 2010 Jul; 65(7):1477-85. PubMed ID: 20462946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
    Gatanaga H; Ode H; Hachiya A; Hayashida T; Sato H; Oka S
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1596-602. PubMed ID: 20124001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
    Diphoko T; Gaseitsiwe S; Kasvosve I; Moyo S; Okatch H; Musonda R; Wainberg M; Makhema J; Marlink R; Novitsky V; Essex M
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):667-671. PubMed ID: 29732907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z; Kuritzkes DR
    J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
    Lai MT; Munshi V; Touch S; Tynebor RM; Tucker TJ; McKenna PM; Williams TM; DiStefano DJ; Hazuda DJ; Miller MD
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2424-31. PubMed ID: 19289522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.
    Lai MT; Lu M; Felock PJ; Hrin RC; Wang YJ; Yan Y; Munshi S; McGaughey GB; Tynebor RM; Tucker TJ; Williams TM; Grobler JA; Hazuda DJ; McKenna PM; Miller MD
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4812-24. PubMed ID: 20805392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
    Azijn H; Tirry I; Vingerhoets J; de Béthune MP; Kraus G; Boven K; Jochmans D; Van Craenenbroeck E; Picchio G; Rimsky LT
    Antimicrob Agents Chemother; 2010 Feb; 54(2):718-27. PubMed ID: 19933797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
    Varghese V; Shahriar R; Rhee SY; Liu T; Simen BB; Egholm M; Hanczaruk B; Blake LA; Gharizadeh B; Babrzadeh F; Bachmann MH; Fessel WJ; Shafer RW
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):309-15. PubMed ID: 19734799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
    ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.
    Bacheler LT; Anton ED; Kudish P; Baker D; Bunville J; Krakowski K; Bolling L; Aujay M; Wang XV; Ellis D; Becker MF; Lasut AL; George HJ; Spalding DR; Hollis G; Abremski K
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2475-84. PubMed ID: 10952598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
    Llibre JM; Santos JR; Puig T; Moltó J; Ruiz L; Paredes R; Clotet B
    J Antimicrob Chemother; 2008 Nov; 62(5):909-13. PubMed ID: 18653487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
    Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
    J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L74V increases the reverse transcriptase content of HIV-1 virions with non-nucleoside reverse transcriptase drug-resistant mutations L100I+K103N and K101E+G190S, which results in increased fitness.
    Wang J; Li D; Bambara RA; Yang H; Dykes C
    J Gen Virol; 2013 Jul; 94(Pt 7):1597-1607. PubMed ID: 23535575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
    Anta L; Llibre JM; Poveda E; Blanco JL; Alvarez M; Pérez-Elías MJ; Aguilera A; Caballero E; Soriano V; de Mendoza C;
    AIDS; 2013 Jan; 27(1):81-5. PubMed ID: 22842995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
    Balamane M; Varghese V; Melikian GL; Fessel WJ; Katzenstein DA; Shafer RW
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4522-4. PubMed ID: 22664973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.